Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction

被引：54

作者：

Malloy, Karla L. ^{[1
,2
]}

Choi, Hyukjae ^{[1
,2
]}

Fiorilla, Catherine ^{[3
]}

Valeriote, Fred A. ^{[4
]}

Matainaho, Teatulohi ^{[5
]}

Gerwick, William H. ^{[1
,2
]}

机构：

[1] Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA

[3] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

[4] Henry Ford Hlth Syst, Dept Internal Med, Josephine Ford Canc Ctr, Detroit, MI 48202 USA

[5] Univ Papua New Guinea, Discipline Pharmacol, Sch Med & Hlth Sci, Natl Capital Dist, Papua N Guinea

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 01期

关键词：

Marine cyanobacteria; Natural products; Lipopeptide; Anticancer; Spectroscopy; P53-MDM2; INTERACTION; P53-HDM2; P53;

D O I：

10.1016/j.bmcl.2011.10.054

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bioassay-guided fractionation of two cyanobacterial extracts from Papua New Guinea has yielded hoiamide D in both its carboxylic acid and conjugate base forms. Hoiamide D is a polyketide synthase (PKS)/non-ribosomal peptide synthetase (NRPS)-derived natural product that features two consecutive thiazolines and a thiazole, as well as a modified isoleucine residue. Hoiamide D displayed inhibitory activity against p53/MDM2 interaction (EC50 = 4.5 mu M), an attractive target for anticancer drug development. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：683 / 688

页数：6

共 17 条

[1]

ALLEY MC, 1988, CANCER RES, V48, P589

[2]

Chène P, 2004, MOL CANCER RES, V2, P20

[3] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].

Chène, P .

NATURE REVIEWS CANCER, 2003, 3 (02) :102-109

[4] The Hoiamides, Structurally Intriguing Neurotoxic Lipopeptides from Papua New Guinea Marine Cyanobacteria [J].

Choi, Hyukjae ;

Pereira, Alban R. ;

Cao, Zhengyu ;

Shuman, Cynthia F. ;

Engene, Niclas ;

Byrum, Tara ;

Matainaho, Teatulohi ;

Murray, Thomas F. ;

Mangoni, Alfonso ;

Gerwick, William H. .

JOURNAL OF NATURAL PRODUCTS, 2010, 73 (08) :1411-1421

[5] Small-molecule inhibitors of MDM2 as new anticancer therapeutics [J].

Dickens, Michael P. ;

Fitzgerald, Ross ;

Fischer, Peter M. .

SEMINARS IN CANCER BIOLOGY, 2010, 20 (01) :10-18

[6] Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. [J].

Duncan, SJ ;

Grüschow, S ;

Williams, DH ;

McNicholas, C ;

Purewal, R ;

Hajek, M ;

Gerlitz, M ;

Martin, S ;

Wrigley, SK ;

Moore, M .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (04) :554-560

[7] Mdm2 facilitates the association of p53 with the proteasome [J].

Kulikov, Roman ;

Letienne, Justine ;

Kaur, Manjit ;

Grossman, Steven R. ;

Arts, Janine ;

Blattner, Christine .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (22) :10038-10043

[8] The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise [J].

Mandinova, Anna ;

Lee, Sam W. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (64)

[9] MUTATIONS IN THE P53 GENE OCCUR IN DIVERSE HUMAN-TUMOR TYPES [J].

NIGRO, JM ;

BAKER, SJ ;

PREISINGER, AC ;

JESSUP, JM ;

HOSTETTER, R ;

CLEARY, K ;

BIGNER, SH ;

DAVIDSON, N ;

BAYLIN, S ;

DEVILEE, P ;

GLOVER, T ;

COLLINS, FS ;

WESTON, A ;

MODALI, R ;

HARRIS, CC ;

VOGELSTEIN, B .

NATURE, 1989, 342 (6250) :705-708

[10]

Patel S, 2008, EXPERT OPIN INV DRUG, V17, P1865, DOI [10.1517/13543780802493366, 10.1517/13543780802493366 ]

← 1 2 →